Interchangeable Biosimilar Automatic Substitution

Jonathan Kay, MD, and Kimberly C. Chen, DO, MSHLM, discuss clinical and financial concerns related to automatic substitution at the pharmacy for an interchangeable biosimilar from a payer perspective.

Related Keywords

Kimberlyc Chen ,Jonathan Kay ,Ryan Haumschild , ,Interchangeable Biosimilar ,Automatic Substitution ,Biosimilars ,Pharmacy ,Payer Perspective ,Reference Product ,Financial Concerns ,Clinical Concerns ,